TY - JOUR
T1 - OSARI, an Open-Source Anticipated Response Inhibition Task
AU - He, Jason L.
AU - Hirst, Rebecca J.
AU - Puri, Rohan
AU - Coxon, James
AU - Byblow, Winston
AU - Hinder, Mark
AU - Skippen, Patrick
AU - Matzke, Dora
AU - Heathcote, Andrew
AU - Wadsley, Corey G.
AU - Silk, Tim
AU - Hyde, Christian
AU - Parmar, Dinisha
AU - Pedapati, Ernest
AU - Gilbert, Donald L.
AU - Huddleston, David A.
AU - Mostofsky, Stewart
AU - Leunissen, Inge
AU - MacDonald, Hayley J.
AU - Chowdhury, Nahian S.
AU - Gretton, Matthew
AU - Nikitenko, Tess
AU - Zandbelt, Bram
AU - Strickland, Luke
AU - Puts, Nicolaas A.J.
N1 - Funding Information:
JLH and NAP received salary support from the Nancy Lurie Marks foundation. RP and DP were supported through an Australian Government Research Training Program stipend. MRH was supported by the Australian Research Council (FT150100406, DP200101696). JPC is supported by an Australian Research Council Discovery project (DP 200100234). EP receives salary support from National Institutes of Health (K23MH112936). DLG has received research support from the NIH (NINDS, NIMH) and the DOD. He has received salary compensation through Cincinnati Children’s for work as a clinical trial site investigator from Emalex (clinical trial, Tourette syndrome) and EryDel (clinical trial, ataxia telangiectasia). He has received book/publication royalties from Elsevier, Wolters Kluwer, and the Massachusetts Medical Society. He has received compensation for expert testimony for the US National Vaccine Injury Compensation Program, through the Department of Health and Human Services. He has received payment for medical expert opinions through Advanced Medical/Teladoc. He has served as a consultant for Applied Therapeutics and Eumentics Therapeutics. SHM has a US patent approved (Patent No: US10,410,041 B2) and his research is supported by grants from the NIH (NINDS, NIMH and NICHD) and NSF and from the Simons Foundation Autism Research Initiative and Waterloo Foundation. IL is supported by an individual EU fellowship (MSCA 798619). DAH has no disclosures. MG has no disclosures.
Funding Information:
JLH and NAP received salary support from the Nancy Lurie Marks foundation. RP and DP were supported through an Australian Government Research Training Program stipend. MRH was supported by the Australian Research Council (FT150100406, DP200101696). JPC is supported by an Australian Research Council Discovery project (DP 200100234). EP receives salary support from National Institutes of Health (K23MH112936). DLG has received research support from the NIH (NINDS, NIMH) and the DOD. He has received salary compensation through Cincinnati Children’s for work as a clinical trial site investigator from Emalex (clinical trial, Tourette syndrome) and EryDel (clinical trial, ataxia telangiectasia). He has received book/publication royalties from Elsevier, Wolters Kluwer, and the Massachusetts Medical Society. He has received compensation for expert testimony for the US National Vaccine Injury Compensation Program, through the Department of Health and Human Services. He has received payment for medical expert opinions through Advanced Medical/Teladoc. He has served as a consultant for Applied Therapeutics and Eumentics Therapeutics. SHM has a US patent approved (Patent No: US10,410,041 B2) and his research is supported by grants from the NIH (NINDS, NIMH and NICHD) and NSF and from the Simons Foundation Autism Research Initiative and Waterloo Foundation. IL is supported by an individual EU fellowship (MSCA 798619). DAH has no disclosures. MG has no disclosures.
Publisher Copyright:
© 2021, Crown.
PY - 2022/6
Y1 - 2022/6
N2 - The stop-signal paradigm has become ubiquitous in investigations of inhibitory control. Tasks inspired by the paradigm, referred to as stop-signal tasks, require participants to make responses on go trials and to inhibit those responses when presented with a stop-signal on stop trials. Currently, the most popular version of the stop-signal task is the ‘choice-reaction’ variant, where participants make choice responses, but must inhibit those responses when presented with a stop-signal. An alternative to the choice-reaction variant of the stop-signal task is the ‘anticipated response inhibition’ task. In anticipated response inhibition tasks, participants are required to make a planned response that coincides with a predictably timed event (such as lifting a finger from a computer key to stop a filling bar at a predefined target). Anticipated response inhibition tasks have some advantages over the more traditional choice-reaction stop-signal tasks and are becoming increasingly popular. However, currently, there are no openly available versions of the anticipated response inhibition task, limiting potential uptake. Here, we present an open-source, free, and ready-to-use version of the anticipated response inhibition task, which we refer to as the OSARI (the Open-Source Anticipated Response Inhibition) task.
AB - The stop-signal paradigm has become ubiquitous in investigations of inhibitory control. Tasks inspired by the paradigm, referred to as stop-signal tasks, require participants to make responses on go trials and to inhibit those responses when presented with a stop-signal on stop trials. Currently, the most popular version of the stop-signal task is the ‘choice-reaction’ variant, where participants make choice responses, but must inhibit those responses when presented with a stop-signal. An alternative to the choice-reaction variant of the stop-signal task is the ‘anticipated response inhibition’ task. In anticipated response inhibition tasks, participants are required to make a planned response that coincides with a predictably timed event (such as lifting a finger from a computer key to stop a filling bar at a predefined target). Anticipated response inhibition tasks have some advantages over the more traditional choice-reaction stop-signal tasks and are becoming increasingly popular. However, currently, there are no openly available versions of the anticipated response inhibition task, limiting potential uptake. Here, we present an open-source, free, and ready-to-use version of the anticipated response inhibition task, which we refer to as the OSARI (the Open-Source Anticipated Response Inhibition) task.
KW - Behavioral Inhibition
KW - Inhibition
KW - Stopping
KW - anticipation
KW - executive functioning
KW - opensource
KW - stop-signal task
UR - http://www.scopus.com/inward/record.url?scp=85118638651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118638651&partnerID=8YFLogxK
U2 - 10.3758/s13428-021-01680-9
DO - 10.3758/s13428-021-01680-9
M3 - Article
C2 - 34751923
AN - SCOPUS:85118638651
VL - 54
SP - 1530
EP - 1540
JO - Behavior Research Methods
JF - Behavior Research Methods
SN - 1554-351X
IS - 3
ER -